Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2010-08-06 Board/Management Inform…
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
8-K Filing
Board/Management Information Classification · 90% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text includes two main items: Item 2.02 announces the company's financial results for the second quarter ended June 30, 2010, and Item 5.02 announces the election of a new director to the Board. The document also references press releases filed as exhibits related to earnings and director election. The document length is 3652 characters, which is relatively short and mainly serves as an announcement rather than containing detailed financial statements or full earnings data. The presence of director election information points to a management/board change announcement. The earnings results announcement is brief and references a press release rather than providing full financial data. Therefore, the primary classification is Board/Management Information (MANG) due to the director election announcement, with a secondary note that earnings results are announced but not detailed here. Given the dual content, the dominant and more specific filing type is MANG.
2010-08-06 English
10-Q Filing
Interim / Quarterly Report Q2 2010
2010-08-06 English
3 Filing
Director's Dealing
2010-07-06 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically details the appointment of a new senior executive officer, Gregory Glenn, as Senior Vice President and Chief Scientific Officer, including terms of employment and compensation. This matches the description of announcements related to changes in the company's board of directors or senior management. There is no financial data or report attached, and the document is not an earnings release or annual report. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence level.
2010-07-06 English
8-K Filing
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 17, 2010, reporting on the Annual Meeting of Stockholders of Novavax, Inc. The content focuses on the submission of matters to a vote of security holders, specifically the election of directors and ratification of the independent auditor. It provides detailed voting results for these proposals. The document is short (2956 characters) and is clearly an official announcement of voting results from the Annual Meeting. It does not contain full financial statements or detailed report content, but rather the outcome of shareholder votes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2010-06-23 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on employment agreements and amendments related to executive officers, including details about salaries, stock options, bonuses, and terms of employment. There is no financial statement or comprehensive financial data presented. The primary subject is changes in senior management and their compensatory arrangements. According to the filing definitions, announcements about changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document is not an annual or quarterly report, nor is it an earnings release or audit report. It is not a proxy statement or remuneration report, as it does not detail compensation comprehensively but rather announces employment agreements. Therefore, the correct classification is MANG with high confidence.
2010-06-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.